Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Keros Therapeutics' Non-Current Assets history spans 7 years, with the latest figure at $22.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 16.32% year-over-year to $22.6 million; the TTM value through Dec 2025 reached $95.5 million, down 3.78%, while the annual FY2025 figure was $22.6 million, 16.32% down from the prior year.
  • Non-Current Assets reached $22.6 million in Q4 2025 per KROS's latest filing, down from $23.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $27.2 million in Q3 2024 to a low of $1.7 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $16.5 million, with a median of $22.1 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: skyrocketed 466.39% in 2023, then fell 16.32% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $3.8 million in 2021, then surged by 451.4% to $21.0 million in 2022, then rose by 8.18% to $22.7 million in 2023, then increased by 18.74% to $27.0 million in 2024, then dropped by 16.32% to $22.6 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Non-Current Assets are $22.6 million (Q4 2025), $23.5 million (Q3 2025), and $24.4 million (Q2 2025).